Assessing Treatment Response of Peritoneal Metastases in Ovarian Cancer Using Diffusion Weighted Magnetic Resonance Imaging.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Ovarian Cancer
- Sponsor
- Institute of Cancer Research, United Kingdom
- Enrollment
- 134
- Locations
- 6
- Primary Endpoint
- Development of a Quantitative Imaging Biomarker for Evaluating Ovarian Cancer Metastases and Assessment of its Potential in Monitoring Treatment Response.
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This project seeks to develop a quantitative imaging biomarker for evaluating and monitoring treatment response in ovarian cancer metastases and assess its potential in monitoring treatment response. This will involve standardising DW-MRI for the abdomen and pelvis across multiple centres and platforms, assessing reproducibility of the measurement in patients planned for neoadjuvant chemotherapy and assessing its utility as an early response biomarker in patients with platinum-sensitive relapse due to receive therapy with carboplatin. Scanning measurements will be correlated with histopathological markers in tumour samples in order to link the biomarker with response mechanisms.
Investigators
Nandita deSouza
Clinical Professor
Institute of Cancer Research, United Kingdom
Eligibility Criteria
Inclusion Criteria
- •Histologically confirmed ovarian, primary peritoneal or fallopian tube cancer stage III or IV
- •Scheduled to receive neoadjuvant chemotherapy (carboplatin/cisplatin)with planned debulking surgery.
Exclusion Criteria
- •Life expectancy of less than 6 months
- •MRI contraindications
- •Low grade or heavily calcified disease
Outcomes
Primary Outcomes
Development of a Quantitative Imaging Biomarker for Evaluating Ovarian Cancer Metastases and Assessment of its Potential in Monitoring Treatment Response.
Time Frame: 4.0 years
Diffusion-weighted magnetic resonance imaging (DW-MRI) for visualising peritoneal metastases will be developed.Reproducibility will be assessed in a multi-centre setting across multiple vendor platforms and field strengths by comparing 2 baseline scans per person and plotting absolute difference in ADC against mean of the 2 measurements.Biological validation will be achieved by correlating scan data (ADC change) following chemotherapy with histology of the tumour(amount of cell death) at surgery.